CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
Primary Purpose
Leukemia, Lymphoma
Status
Active
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
SCRI-huCAR19v1
SCRI-huCAR19v2
Sponsored by
About this trial
This is an interventional treatment trial for Leukemia focused on measuring CAR T cell, CD19, pediatric, young adults
Eligibility Criteria
Inclusion Criteria:
- Male and female subjects age ≥ 1 and ≤ 30 years
- First 2 enrolled subjects: age ≥ 18 and ≤ 30 years
Disease requirements:
- Phase 1: Evidence of refractory or recurrent CD19+ leukemia or lymphoma following previous CAR T cell immunotherapy
- Phase 2: Evidence of refractory or recurrent CD19+ leukemia or lymphoma
- Able to tolerate apheresis, or has sufficient existing apheresis product or T cells for manufacturing investigational product
- Life expectancy ≥ 8 weeks
- Lansky or Karnofsky, as applicable, score ≥ 50
- Recovered from acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy, if the subject does not have a previously obtained apheresis product that is acceptable and available for manufacturing of CAR T cells
- ≥ 7 days post last chemotherapy and biologic therapy, with the exception of intrathecal chemotherapy and maintenance chemotherapy
- No prior virotherapy
- ≥ 7 days post last corticosteroid therapy
- ≥ 3 days post Tyrosine Kinase Inhibitor (TKI) use
- ≥ 1 day post hydroxyurea
- 30 days post most recent CAR T cell infusion
- Adequate organ function
- Adequate laboratory values, including absolute lymphocyte count ≥ 100 cells/uL
- Subjects of childbearing or child-fathering potential must agree to use highly effective contraception from consent through 12 months following infusion of investigational product on trial
- Subject and/or legally authorized representative has signed the informed consent form for this study
Exclusion Criteria:
- Presence of active malignancy other than disease under study
- History of symptomatic CNS pathology or ongoing symptomatic CNS pathology
- CNS involvement of leukemia or lymphoma that is symptomatic and in the opinion of the investigator, cannot be controlled during the interval between enrollment and CAR T cell infusion
- Presence of active GVHD, or receiving immunosuppressive therapy for treatment or prevention of GVHD within 4 weeks prior to enrollment
- Presence of active severe infection
- Presence of primary immunodeficiency syndrome
- Subject has received prior virotherapy
- Pregnant or breastfeeding
- Subject and/or legally authorized representative unwilling to provide consent/assent for participation in the 15-year follow up period, required if CAR T cell therapy is administered
- Presence of any condition that, in the opinion of the investigator, would prohibit the patient from undergoing treatment under this protocol
Sites / Locations
- Children's Hospital Los Angeles
- Seattle Children's Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
SCRI-huCAR19v2
SCRI-huCAR19v1 - [CLOSED]
Arm Description
Patients will receive SCRI-huCAR19v2 in either Phase 1 or Phase II
Patients will receive SCRI-huCAR19v1 in either Phase 1 or Phase II. As of 02/13/2020 this study cohort is permanently closed.
Outcomes
Primary Outcome Measures
The adverse events associated with CAR T cell product infusions will be assessed
The type, frequency, severity, and duration of adverse events will be summarized
The leukemia response to SCRI-huCAR19 in subjects with relapsed or refractory CD19+ leukemia will be assessed
Response will be defined by standard bone marrow assessment and standard response criteria
Secondary Outcome Measures
Full Information
NCT ID
NCT03684889
First Posted
September 17, 2018
Last Updated
June 27, 2023
Sponsor
Seattle Children's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03684889
Brief Title
CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
Official Title
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-06: A Phase 1/2 Study of CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 28, 2018 (Actual)
Primary Completion Date
February 8, 2021 (Actual)
Study Completion Date
December 2036 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seattle Children's Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a fully human chimeric antigen receptor (CAR). The CAR used in this study can recognize CD19, a protein expressed on the surface of leukemia and lymphoma cells. The fully human CAR used in this study may help protect against rejection of the CAR T cells, which in turn could lead to lasting protection against return of the leukemia or lymphoma. The phase 1 part of this study will determine the safety of these CAR T cells, and the phase 2 part of the study will determine how effective this CAR T cell therapy is. Both patients who have never had prior CAR T cell therapy and those who have had prior CAR T cell therapy may be eligible to participate in this study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia, Lymphoma
Keywords
CAR T cell, CD19, pediatric, young adults
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
SCRI-huCAR19v2
Arm Type
Experimental
Arm Description
Patients will receive SCRI-huCAR19v2 in either Phase 1 or Phase II
Arm Title
SCRI-huCAR19v1 - [CLOSED]
Arm Type
Experimental
Arm Description
Patients will receive SCRI-huCAR19v1 in either Phase 1 or Phase II. As of 02/13/2020 this study cohort is permanently closed.
Intervention Type
Biological
Intervention Name(s)
SCRI-huCAR19v1
Intervention Description
1:1 mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
Intervention Type
Biological
Intervention Name(s)
SCRI-huCAR19v2
Intervention Description
Mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
Primary Outcome Measure Information:
Title
The adverse events associated with CAR T cell product infusions will be assessed
Description
The type, frequency, severity, and duration of adverse events will be summarized
Time Frame
30 days
Title
The leukemia response to SCRI-huCAR19 in subjects with relapsed or refractory CD19+ leukemia will be assessed
Description
Response will be defined by standard bone marrow assessment and standard response criteria
Time Frame
63 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female subjects age ≥ 1 and ≤ 30 years
First 2 enrolled subjects: age ≥ 18 and ≤ 30 years
Disease requirements:
Phase 1: Evidence of refractory or recurrent CD19+ leukemia or lymphoma following previous CAR T cell immunotherapy
Phase 2: Evidence of refractory or recurrent CD19+ leukemia or lymphoma
Able to tolerate apheresis, or has sufficient existing apheresis product or T cells for manufacturing investigational product
Life expectancy ≥ 8 weeks
Lansky or Karnofsky, as applicable, score ≥ 50
Recovered from acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy, if the subject does not have a previously obtained apheresis product that is acceptable and available for manufacturing of CAR T cells
≥ 7 days post last chemotherapy and biologic therapy, with the exception of intrathecal chemotherapy and maintenance chemotherapy
No prior virotherapy
≥ 7 days post last corticosteroid therapy
≥ 3 days post Tyrosine Kinase Inhibitor (TKI) use
≥ 1 day post hydroxyurea
30 days post most recent CAR T cell infusion
Adequate organ function
Adequate laboratory values, including absolute lymphocyte count ≥ 100 cells/uL
Subjects of childbearing or child-fathering potential must agree to use highly effective contraception from consent through 12 months following infusion of investigational product on trial
Subject and/or legally authorized representative has signed the informed consent form for this study
Exclusion Criteria:
Presence of active malignancy other than disease under study
History of symptomatic CNS pathology or ongoing symptomatic CNS pathology
CNS involvement of leukemia or lymphoma that is symptomatic and in the opinion of the investigator, cannot be controlled during the interval between enrollment and CAR T cell infusion
Presence of active GVHD, or receiving immunosuppressive therapy for treatment or prevention of GVHD within 4 weeks prior to enrollment
Presence of active severe infection
Presence of primary immunodeficiency syndrome
Subject has received prior virotherapy
Pregnant or breastfeeding
Subject and/or legally authorized representative unwilling to provide consent/assent for participation in the 15-year follow up period, required if CAR T cell therapy is administered
Presence of any condition that, in the opinion of the investigator, would prohibit the patient from undergoing treatment under this protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Colleen Annesley, MD
Organizational Affiliation
Seattle Children's Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Children's Hospital Los Angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90027
Country
United States
Facility Name
Seattle Children's Hospital
City
Seattle
State/Province
Washington
ZIP/Postal Code
98105
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
We'll reach out to this number within 24 hrs